Hypothalamic ObesityPhase 2NCT05147415
Study of Tesomet With Open-label Extension in Subjects With Hypothalamic Obesity (HO)
A Phase 2 study testing Tesomet in people with Hypothalamic Obesity, run by Saniona at 1 site in United States.
Trial summary
This study will evaluate the safety and efficacy of Tesomet (tesofensine + metoprolol) in subjects 18 years of age or older, with HO Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hypothalamic Obesity
- What is being tested?
- Tesomet
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 0 participants
- Where
- 1 siteUnited States
- Study dates
- 11 Nov 2021to 9 Dec 2022
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Subject and, if applicable, their parent or legal guardian must be willing to provide informed consent
- Diagnosis of HO secondary to damage to the hypothalamus
- Female subjects must be of non-childbearing potential
- At least 6 months since completion of therapy (chemotherapy, surgery, or radiation with resulting injury to the hypothalamus and/or the pituitary) with stable disease and lack of recurrence
- BMI 30.0 to 60.0 kg/m², inclusive
- Documented stable body weight (gain/loss <10%) for at least 90 days prior to Screening
- Stable and well-managed pituitary replacement (eg, glucocorticoid, thyroid hormone, estrogen/progestin or testosterone, desmopressin, or growth hormone) for >2 months prior to Screening
- Male subjects who are sexually active must be surgically sterile
Who cannot join
- Females who are pregnant, breastfeeding, or actively intending to become pregnant during the study
- Sitting BP that meets the following criteria after 5 minutes of rest at Screening:
- Systolic BP >145 mmHg or <100 mmHg; or
- Diastolic BP >95 mmHg or <70 mmHg
- Type 1 diabetes mellitus
- History of major depressive disorder within 2 years prior to Screening, or any history of other severe psychiatric disorder (eg, schizophrenia, bipolar disorder)
Show all 9Show fewer
- Uncontrolled endocrine disorders (eg, Cushing syndrome, Addison's, hypothyroidism, hyperthyroidism)
- History of bulimia or anorexia nervosa
- Use of prohibited medications, including current use of selective serotonin reuptake inhibitors / serotonin-norepinephrine reuptake inhibitors (SSRIs/SNRIs)
Trial locations and contacts
1 site in 1 country.
United States1 site
Sparrow Clinical Research Institute
Lansing, Michigan, 48912
About this study
Official title: A Phase 2b, Double-blind, Randomized, Placebo-controlled, Dose-finding, Multi-center, 36-week Safety and Efficacy Study With Open-label Extension (OLE) Period of Tesomet in Subjects With Hypothalamic Obesity
This study will evaluate the safety and efficacy of Tesomet (tesofensine + metoprolol) in subjects 18 years of age or older, with HO
- Conditions
- Hypothalamic Obesity
- Being tested
- Placebo, Tesomet
- Medical subject headings
- Sexual Infantilism
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PlaceboOther
Inactive comparator
TesometDrug
Also called tesofensine, metoprolol
Fixed-dose combination
| Study group | Role | What they receive |
|---|---|---|
| Placebo | Placebo comparator | Once-daily PO for 36 weeks during the double-blind period; then if continued eligible for OLE, once-daily dosing for 36 weeks at the highest tolerated Tesomet dose from the double-blind period Receives: Other: Placebo; Drug: Tesomet |
| Tesomet Low Dose | Experimental | Once-daily PO for 36 weeks during the double-blind period; then if continued eligible for OLE, once-daily dosing for 36 weeks at the highest tolerated dose from the double-blind period Receives: Drug: Tesomet |
| Tesomet Medium Dose | Experimental | Once-daily PO for 36 weeks during the double-blind period; then if continued eligible for OLE, once-daily dosing for 36 weeks at the highest tolerated dose from the double-blind period Receives: Drug: Tesomet |
| Tesomet High Dose | Experimental | Once-daily PO for 36 weeks during the double-blind period; then if continued eligible for OLE, once-daily dosing for 36 weeks at the highest tolerated dose from the double-blind period Receives: Drug: Tesomet |
What is being measured
The primary outcome is the main question the study is designed to answer.
Body weight (%)
Percentage change in body weight
Measured: Baseline to Week 36
Secondary outcomes (4)
Body weight loss
Proportion of subjects who meet pre-specified thresholds for body weight loss
Measured: Week 36
Body weight (kg)
Change in body weight in kilograms
Measured: Baseline to Week 36
Waist circumference (cm)
Change in waist circumference in centimeters
Measured: Baseline to Week 36
Body Mass Index (BMI)
Change in BMI
Measured: Baseline to Week 36
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Dec 2021
- Study start11 Nov 2021
- Primary completion9 Dec 2022
- Study completion9 Dec 2022
Why it stopped: Due to financial considerations Sponsor is unable to complete the trial and assess the planned objectives/endpoints. No subjects have been randomized to treatment in the clinical trial and the decision therefore has no safety concern for patients
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hypothalamic ObesityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Saniona
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Sophie Guillaume, MS, Study director, Saniona
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05147415
- Sponsor's protocol ID
- TM008
- Status last verified
- Dec 2022
- First submitted
- 24 Nov 2021
- Last updated
- 13 Dec 2022
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: The Sponsor will consider requests from qualified researchers for access to TM008 study materials
Study at a glance
From the registry record, last updated by the sponsor on 13 Dec 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 2b, Double-blind, Randomized, Placebo-controlled, Dose-finding, Multi-center, 36-week Safety and Efficacy Study With Open-label Extension (OLE) Period of Tesomet in Subjects With Hypothalamic Obesity
- ClinicalTrials.gov ID
- NCT05147415
- Acronym / sponsor ID
- TM008
- Conditions
- Hypothalamic Obesity
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- WithdrawnReason stopped: Due to financial considerations Sponsor is unable to complete the trial and assess the planned objectives/endpoints. No subjects have been randomized to treatment in the clinical trial and the decision therefore has no safety concern for patients
- Enrolment
- 0 participants (actual)
- Lead sponsor
- SanionaIndustry (pharma, biotech, devices)
- Study start
- 11 Nov 2021 (actual)
- Primary completion
- 9 Dec 2022 (actual)
- Study completion
- 9 Dec 2022 (actual)
- First posted
- 7 Dec 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will evaluate the safety and efficacy of Tesomet (tesofensine + metoprolol) in subjects 18 years of age or older, with HO
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Placebo | Placebo comparator | Other: Placebo, Drug: TesometOnce-daily PO for 36 weeks during the double-blind period; then if continued eligible for OLE, once-daily dosing for 36 weeks at the highest tolerated Tesomet dose from the double-blind period |
| Tesomet Low Dose | Experimental | Drug: TesometOnce-daily PO for 36 weeks during the double-blind period; then if continued eligible for OLE, once-daily dosing for 36 weeks at the highest tolerated dose from the double-blind period |
| Tesomet Medium Dose | Experimental | Drug: TesometOnce-daily PO for 36 weeks during the double-blind period; then if continued eligible for OLE, once-daily dosing for 36 weeks at the highest tolerated dose from the double-blind period |
| Tesomet High Dose | Experimental | Drug: TesometOnce-daily PO for 36 weeks during the double-blind period; then if continued eligible for OLE, once-daily dosing for 36 weeks at the highest tolerated dose from the double-blind period |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Subject and, if applicable, their parent or legal guardian must be willing to provide informed consent
- Diagnosis of HO secondary to damage to the hypothalamus
- Female subjects must be of non-childbearing potential
- At least 6 months since completion of therapy (chemotherapy, surgery, or radiation with resulting injury to the hypothalamus and/or the pituitary) with stable disease and lack of recurrence
- BMI 30.0 to 60.0 kg/m², inclusive
Key exclusion criteria (9 listed)
- Females who are pregnant, breastfeeding, or actively intending to become pregnant during the study
- Sitting BP that meets the following criteria after 5 minutes of rest at Screening:
- Type 1 diabetes mellitus
- History of major depressive disorder within 2 years prior to Screening, or any history of other severe psychiatric disorder (eg, schizophrenia, bipolar disorder)
- Uncontrolled endocrine disorders (eg, Cushing syndrome, Addison's, hypothyroidism, hyperthyroidism)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PlaceboInactive comparator | Other | Placebo |
| TesometAlso: tesofensine, metoprololFixed-dose combination | Drug | Placebo, Tesomet High Dose, Tesomet Low Dose, Tesomet Medium Dose |
Primary outcome
Body weight (%)
Time frame: Baseline to Week 36
Percentage change in body weight
4 secondary outcomes
Body weight loss
Time frame: Week 36
Body weight (kg)
Time frame: Baseline to Week 36
Waist circumference (cm)
Time frame: Baseline to Week 36
Body Mass Index (BMI)
Time frame: Baseline to Week 36
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Dec 2022.
- Individual participant dataSharing planned: Yes. The Sponsor will consider requests from qualified researchers for access to TM008 study materials
Related trials for Hypothalamic Obesity
Recruiting
Hypothalamic GLP-1 Response in Healthy Weight and Obesity
Obesity, Normal Weight
Recruiting
Clinical Study on Circadian Genes Dysregulation in Patients With Glucocorticoid Disorders
Cushing Syndrome, Adrenal Insufficiency
Active, not recruitingPhase 2
Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity
Hypothalamic Obesity, Hypothalamic Tumor
Active, not recruitingPhase 1/2
A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment
Hypothalamic Obesity, Prader-Willi Syndrome
Not yet recruitingPhase 3
SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years
Craniopharyngioma, Child
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sophie Guillaume, MS study director
Saniona
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Tesomet in people with Hypothalamic Obesity, run by Saniona at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 13 Dec 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Body weight (%) (time frame: Baseline to Week 36). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Dec 2022.